check_circleStudy Completed
Non Small Cell Lung Cancer
Bayer Identifier:
91411
ClinicalTrials.gov Identifier:
EudraCT Number:
EU CT Number:
Not Available
Safety and efficacy study of a new chemotherapy agent to treat non small cell lung cancer.
Trial purpose
The purpose of this study is to determine whether the study drug is effective and safe in the treatment of patients with non small cell lung cancer who have already received one platinum based chemotherapy.
Key Participants Requirements
Sex
BothAge
18 YearsTrial summary
Enrollment Goal
112Trial Dates
March 2005 - November 2008Phase
Phase 2Could I Receive a placebo
NoProducts
VEGF-Tyrosine Kinase Inhibitor (BAY86-5127)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Universitätsklinikum Essen | Essen, 45122, Germany |
Completed | Universitätsmedizin der Georg-August-Universität Göttingen | Göttingen, 37075, Germany |
Completed | Institut Gustave Roussy | Villejuif, 94805, France |
Completed | Hospital Tenon | Paris, 75970, France |
Completed | Hospital de la Pitie Salpetriere Service Oncologie Medicale | Paris, 75651, France |
Completed | Johannes-Gutenberg-Universität Mainz | Mainz, 55131, Germany |
Primary Outcome
- Tumor response rate (complete or partial response according to RECIST).date_rangeTime Frame:At baseline and every 8 weeks afterwardsenhanced_encryptionyesSafety Issue:
Secondary Outcome
- Time to disease progression.date_rangeTime Frame:At baseline and every 8 weeks afterwardsenhanced_encryptionyesSafety Issue:
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
Non-randomizedBlinding
Open LabelAssignment
Single Group AssignmentTrial Arms
2